Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

02624 MINIMALLY INVASIVE ASSESSMENT OF MUCOSAL INFLAMMATION USING RECTAL SWABS

Elliott, Julie*
Zuckerman, R# , Lucchetti A**, Fuerst, M*, Celum, C#, Anton, P*, McGowan, I*
*The David Geffen School of Medicine At Ucla,Los Angeles,USA, # University of Washington, Seattle, USA, ** IMpacta, Lima Peru.

Rationale: Previous studies have linked mucosal inflammation and disruption to increased risk of HIV-1 infection. Nonoxynol-9 has been linked to increased HIV transmission, possibly via IL-1b mediated activation in vaginal mucosa. For assessment of safety of topical microbicides, minimally invasive, sensitive techniques are needed to assess biologic correlates of mucosal inflammation. We report pilot data on the measurement of IL-1b and calprotectin expression by RT-PCR in cells eluted from rectal swabs. Both IL-1b and calprotectin are known to be increased in mucosal inflammation Methods: Investigations using cell lines were performed to optimize cell number and RNA recovery from swabs. Rectal swabs (n=29) were collected from five antiretroviral naïve Peruvian HIV+ subjects (median CD4 492 cells/?L; range (313-581), enrolled in an ongoing randomized, double blind, placebo controlled trial evaluating the effect of valacyclovir on herpes and HIV shedding. Swabs were inserted 3 cm from the anal margin and rotated once 360o and immediately stored in RNAlater. IL-1b and calprotectin expression were determined by real time PCR and expressed relative to normal, uninflamed colon RNA. Results: b-actin signals were seen for all the samples processed. IL-1b expression was determined in 20/29 subjects with a range of 0.2-2000 fold increase over normal; calprotectin in 27/29 subjects with a range of 3-5000 fold normal. Conclusions: These preliminary data demonstrate the feasibility of using rectal swabs to determine the presence of biologic markers of rectal inflammation in clinical trial subjects. Future studies are required to prospectively evaluate the correlation between the expression levels of IL-1b and calprotectin in rectal swabs with endoscopic, histological, and fecal calprotectin derived evidence of inflammation.

Julie Elliott
MRL 1529, 675 Charles Young Drive South, Los Angeles, CA 90095-7019
(Telephone) 011-310-794-7195 (Fax) 011-267-0289 (E-mail) jelliott@mednet.ucla.edu